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Abstract: Prostate cancer is widely observed to be biologically heterogeneous. Its 
heterogeneity is manifested histologically as multifocal prostate cancer, which is observed 
more frequently than unifocal prostate cancer. The clinical and prognostic significance of 
either focal cancer type is not fully established. To investigate prostate cancer 
heterogeneity, the genetic profiles of multifocal and unifocal prostate cancers were 
compared. Here, we report observations deduced from tumor-tumor comparison of copy 
number alteration data of both focal categories. Forty-one fresh frozen prostate cancer foci 
from 14 multifocal prostate cancers and eight unifocal prostate cancers were subjected to 
copy number variation analysis with the Affymetrix SNP 6.0 microarray tool. With the 
investigated cases, tumors obtained from a single prostate exhibited different genetic 
profiles of variable degrees. Further comparison identified no distinct genetic pattern or 
signatures specific to multifocal or unifocal prostate cancer. Our findings suggest that 
samples obtained from multiple sites of a single unifocal prostate cancer show as much 
genetic heterogeneity and variability as separate tumors obtained from a single multifocal  
prostate cancer. 
Keywords: prostate cancer; multifocal; unifocal; copy number variation;  
heterogeneity; affymetrix  
 
1. Introduction 
Prostate cancer is the second most common cancer in men worldwide and the most frequently 
diagnosed cancer in men in Europe [1]. The complex and heterogeneous nature of prostate cancer 
remains a challenge that negatively influences clinical management of the disease. A major feature of 
prostate cancer complexity is the presence of multiple adenocarcinoma foci in 50% to 76% of radical 
prostatectomy specimens [2,3]. The multifocal status is identified during pathological evaluation as the 
presence of two or more cancer foci distinctly separated [2,3]. The unifocal prostate cancer has been 
described as a single anatomical cancer focus present in about 33% of radical prostatectomy  
specimens [4,5]. A report from Djavan et al. [5] associated high Gleason scores and tumor stage to 
multifocal prostate cancer and also proposed ―multifocality‖ to be a predictor of recurrence [5]. In the 
view of many researchers, the multifocal nature of most prostate cancers has been blamed for the 
poorly predictable biological behavior of many cases and the difficulty in fully understanding  
its pathogenesis. [2,6,7].  
In recent times, the use of microarray technologies has contributed immensely in prostate cancer 
research and generated a wealth of knowledge on the structural variations of the cancer genome. The 
dual-utilization of SNP (single nucleotide polymorphism) and CNV (copy number variation) markers 
in the Affymetrix SNP 6.0 microarray tool provides increased genomic resolution and an extensive 
mapping of the genome. This microarray tool is capable of identifying copy number changes and loss 
of heterozygosity, which have an influential role in altering gene expression levels, gene function and 
increasing disease susceptibility [8–10]. Exploiting the advantages of this high resolution SNP-CNV 
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tool provides us with the possibility of investigating the prostate cancer genome and producing a 
characterized copy number profile for all tumors investigated.  
With the growing need to understand the implication and existence of multifocal and unifocal 
prostate cancer, this study utilized radical prostatectomy specimens categorized by the number of 
tumor foci present. Forty-one fresh frozen prostate cancer samples and nine non-tumor samples from 
blood and normal prostate tissue were utilized. A high-resolution characterization of the tumor foci 
would enable the comparison of multifocal prostate cancers and unifocal prostate cancers to further 
investigate the heterogeneity of prostate cancer.  
2. Results and Discussion 
2.1. Chromosomal CNV Events 
All tumor samples had a mean intensity QC (quality control) value of 96.5%, median of 96.79% 
and min-max range of 90.34%–98.94%. For the eight blood samples and one normal tissue sample, the 
mean QC value was 98.01%, median of 98.38% and min-max range of 96.79%–98.78%. The 
concordance check was conducted to ascertain that individual tumor pairs were indeed from the same 
prostate. All tumor pairs show concordance when called-SNPs were compared (Supplementary 
Information, Table S1). With the exclusion of CNV alterations present in both tumor and non-tumor 
samples, genome-wide CNV data obtained from 41 tumor samples showed somatic alterations  
(Figure 1) that were similar to earlier genomic studies [11–13]. Utilizing a minimum observation 
frequency of five tumors with CNV alterations, the most frequent gains were observed on these 
chromosomal regions: 1p36.13 (17/41, 41.5%), 1q21.2 (8/41, 19.5%), 7q35 (8/41, 19.5%) and 15q11.2 
(5/41, 12.2%). Copy number losses were observed predominantly on chromosome regions 8p. The 
most recognized were 8p21.2 (22/41, 53.7%), 8p21.3 (20/41, 48.8%), 8p21.1 (19/41, 46.3%) and 
8p21.2–8p21.1 (19/41, 46.3%). Other frequently observed losses were situated on 21q22.2–21q22.3 
(13/41, 31.7%), 13q14.13 (12/41, 29.3%), 16q24.1–16q24.2 (12/41, 29.3%), 10q23.31 (11/41, 26.8%) 
and 17p13.1 (10/41, 24.4%) (Figure 1).  
Chromosomal losses on 8p, 10q, 13q and 16q were observed most frequently in our study (Figure 1; 
Supplementary Information, Table S2). These aberrations correlate closely with CNV data from 
previous studies [14–16]. Notable chromosomal gains on 8q were not observed frequently in this 
study, but were identified in four distinct tumor foci specimens—MS50R, MS235L, MS368R and 
MS407L, which interestingly were tumors with high Gleason scores (Table 1). This observation does 
support the reported correlation between the gains observed on 8q and higher Gleason score [17,18]. In 
addition, low frequency of observed 8q gain may have been influenced by our tumor sample selection, 
which was restricted to organ-confined cancers, since 8q gains have been reported to be associated 
with advanced prostate cancer cases [17]. 
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Figure 1. Most frequent copy number alterations in 41 tumor foci from 22 patients. (Color 
representations: red indicates losses observed in both tumor samples from a single prostate; 
brown indicates losses in one out of two tumor samples from a single prostate; blue 
indicates gains in both tumor samples from a single prostate; green indicates gains in one 
out of two tumor samples from a single prostate). (*) Matching left samples from these 
cases: MS34, MS173 and MS334 were not investigated, due to insufficient tumor quantity.  
 
































66 4 + 3 
3 + 4 
pT3a cT2c 2.1 
0.7 
multifocal 2 
MS50R 4 + 3 1.4 
MS151L 
61 4 + 3 
4 + 3/3 + 3 
pT3b cT2c 2.85 
0.76 
multifocal 2 
MS151R 4 + 3 2.09 
MS183L 
59 4 + 3 
3 + 4 
pT3a cT2b 7.35 
0.35 
multifocal 2 
MS183R 3 + 4 7.0 
MS210L 
62 3 + 3 
3 + 3 
pT3b cT2c 8.64 
4.16 
multifocal 2 
MS210R 3 + 3 4.48 
MS235L 
65 4 + 5 
4 + 4/4 + 5 
pT3a cT2b 12.5 
12.0 
multifocal 2 
MS235R 3 + 3/3 + 4 0.5 
MS343L 
57 2 + 3 
3 + 3 
pT2b cT2b 1.33 
0.95 
multifocal 3 
MS343R 3 + 4/3 + 3 0.19 
MS368L 
65 4 + 5 
3 + 4 
pT3c cT2b 13.76 
2.56 
multifocal 2 
MS368R 4 + 5 11.2 
MS407L 
51 3 + 4 
3 + 4/4 + 3 
pT2b cT2c 1.35 
0.81 
multifocal 2 
MS407R 3 + 3/3 + 4 0.54 
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Table 1. Cont. 
Sample ID: MS = Muenster Bio-bank, RD = Rotterdam Bio-bank, location of prostate from which the tumor foci was obtained (L = left, 
R = right). Where two Gleason scores (GS) are stated: GS of upper cut-section of tumor/GS of bottom cut-section of tumor. Matching 
blood specimens were analyzed from MS50, MS151, MS368, MS840, MS971, MS34, MS334, MS38 and normal prostate tissue from 
RD819. *MS34L, MS173L and MS334L had insufficient tumor quantity and were thus excluded. Full table: Supplementary Information, 
Table S3. 
2.2. Comparison of Copy Number Profile Observed in Multifocal and Unifocal Prostate Cancers 
Genome-wide analysis of 28 multifocal and 13 unifocal prostate cancer foci enabled the comparison 
of prostate cancer focal categories. To identify contrasting alterations, separate chromosomal 
karyoviews of multifocal and unifocal prostate cancers were scrutinized (Figure 2). Comparison 
identifies no exclusive chromosomal alteration that occurs frequently in any particular ―focality‖ 
group. Frequent genetic alterations observed in multifocal prostate cancers were also present in some 
Sample ID 
Patient age 



























53 3 + 2 
3 + 3 
pT2c cT1c 4.55 
0.7 
multifocal 5 
MS586R 3 + 3 1.4 
MS840L 
66 4 + 3 
3 + 4 
pT3a cT2c 2.64 
1.44 
multifocal 4 
MS840R 3 + 4 0.48 
MS898L 
54 4 + 3 
3 + 4/3 + 3 
pT2c cT1c 3.5 
0.35 
multifocal 3 
MS898R 3 + 4 2.8 
MS946L 
61 3 + 2 
3 + 3 
pT3a cT2b 6.75 
6.3 
multifocal 2 
MS946R 3 + 3 0.45 
MS971L 
50 4 + 5 
3 + 4 
pT3a cT2a 1.26 
1.08 
multifocal 2 
MS971R 3 + 4 0.18 
RD819L 
52 NA 
3 + 3 
pT3a cT1c NA 
NA 
multifocal 2 
RD819R 3 + 3 NA 
*MS34L 
71 4 + 3 
NA 
pT2a cT1c 4.56 unifocal 1 
MS34R 4 + 3 
MS38L 
62 3 + 4 
3 + 3 
pT3c cT2c 22.4 unifocal 1 
MS38R 3 + 3 
MS78L 
66 3 + 3 
3 + 3 
pT3a cT2b 3.08 unifocal 1 
MS78R 3 + 3 
MS99L 
57 3 + 4 
3 + 3 
pT3a cT2c 4.42 unifocal 1 
MS99R 3 + 3 
*MS173L 
59 3 + 3 
NA 
pT3b cT2b 1.2 unifocal 1 
MS173R 3 + 3 
*MS334L 
67 4 + 4 
NA 
pT3c cT2c 15.96 unifocal 1 
MS334R 3 + 3 
MS470L 
64 3 + 4 
3 + 3 
pT3a cT2b 11.27 unifocal 1 




pT4 NA 45.75 unifocal 1 
MS1096R 3+3 
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unifocal prostate cancers and vice versa. From the multifocal prostate cancer karyoview (Figure 2A), 
gains on chromosome 8q were observed in four tumor specimens (MS50R, MS235L, MS368R and 
MS407L). Though this aberration on 8q was not observed in any unifocal prostate cancer (Figure 2B), 
the low frequency of this event (n = 4) leaves it unspecific for multifocal prostate cancers specimens.  
Figure 2. Summary of all tumors in a karyoview. (A) Multifocal prostate cancers;  
(B) Unifocal prostate cancers. Regions of blue and red are specific to regions of gains and 
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The absence of a clear-cut genetic difference between the multifocal and unifocal prostate cancers 
reaffirms that prostate cancer is a heterogeneous disease, and the genetic characteristics or biological 
behavior of a prostate cancer case is unlikely to be predicted by just the number of tumor foci present 
in the prostate. As already suggested by earlier studies, specific clonal cancer cell populations may be 
responsible for the aggressiveness of some prostate cancer cases [2,19]. Our data support these 
assumptions, and we also suggest that aggressive potential can be found in both multifocal and 
unifocal prostate cancers and cannot be specifically attributed to a distinct ―focality‖ group.  
2.3. Hierarchical Clustering 
The copy number variation data of samples from multifocal and unifocal prostate cancer were 
subjected to hierarchical clustering (Figure 3). Copy number losses and gains located on chromosomes 
1 to 22 were utilized in the Partek
®
 Genomic Suite environment (St. Louis, MO, USA). Due to 
artificial copy number loss on the X and Y chromosome, the genetic data on these chromosomes were 
not utilized for the clustering process. The hierarchical clustering of all cases shows clusters of tumors 
with congruent copy number profiles.  
Six tumor pairs from these multifocal prostate cancers—MS151, MS586, MS898, MS946, MS971 
and RD819—were closely clustered, due to strong similarities in CNV profiles (Figure 3A). These 
tumor pairs may have progressed from a single cancer cell population, because of their largely similar 
genetic profiles. However, some potentially critical genetic differences were detected and highlighted 
in Figure 4. The loss of PTEN was found distinctly in the right tumor of MS151, the loss of NKX3 -1 
was located in the left tumor of MS586 and the right tumor of RD819 and the loss of ETV6 and 
TMPRSS2 was found in the right tumor of MS898. These observations show that some tumor pairs 
from single prostates share several genetic similarities, but still possess few and possibly critical 
genetic differences. With the other cases, multifocal tumors from different patients were observed to 
be closely clustered. Here, tumor pairs from the same prostate were not found on the same cluster, due 
to dissimilar CNV profiles. Multifocal tumor pairs with the most dissimilar CNV profiles (MS50, 
MS235, MS343, MS368 and MS407) indicated an evolution of tumor foci from separate clonal cell 
ancestry. The presence of separate tumor foci has been described to originate from different cell 
origins, advance at dissimilar rates and, thus, accumulating very different degrees of genetic  
alterations [6,20]. With these observations, it is revealing that within multifocal prostate cancer, tumor 
foci can be variably different; while some tumor foci from a single prostate share large genetic 
alteration, other tumor foci have very few genetic alterations in common. 
The unifocal prostate cancers possess larger tumor volumes than the individual tumor foci in 
multifocal prostate cancers (Table 1). The unifocal tumors have a mean tumor volume of 13.6 cm
3
, 
while the multifocal tumor foci have a mean tumor volume of 2.5 cm
3
. Analyzed tumors obtained  
from two flanks of a single focus showed that tumor pairs from these unifocal prostate cancer 
specimens—MS38, MS78, MS99, MS470 and MS1096 (Figure 3B)—possess dissimilar genetic 
profiles, i.e., tumor pairs from a single focus were not present in a single cluster. From the cluster 
diagram (Figure 3B), the unifocal prostate cancer specimens exhibited heterogeneity within the single 
focus, and it has been suggested to be borne from the possible confluence of multiple separate tumor 
foci. Unifocal prostate cancer can be said to be initiated by the progression of independent smaller 
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tumor foci, from which, as time elapses, the tumor foci merge to form a tumor mass, which has a much 
larger tumor volume and possesses different genetic alterations depending on the area of the tumor  
investigated [6,7]. It was also suggested that unifocal prostate cancer may be a phenotypic 
representation of prostate cancer in its late stages [21]. In this study, unifocal prostate cancer was 
observed to be as heterogeneous as multifocal prostate cancer, due to the possible fusion of several 
tumor foci of possibly different biological characteristics. 
Figure 3. Hierarchical clustering of copy number summary from chromosome 1 to 22. 
(Heat map: red represents gene losses, blue represents gene gains and grey represents 
unchanged gene states). Blue oval symbols denote tumors from the same prostate that 
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2.4. Copy Number Altered Genes Elucidate Prostate Cancer Heterogeneity  
Our study also reveals that alteration of some notable genes was not observed uniformly in tumor 
pairs from multifocal and unifocal prostate cancer specimens. Genes selected from the Cancer Genome 
Project [22] and reported to be frequently altered in prostate cancer [23] were detected variably in 
tumor pairs from single prostates (Figure 4). The presence of ―altered prostate cancer-related genes‖ 
elucidates the genetic heterogeneity in multifocal and unifocal prostate cancers.  
Figure 4. Observed copy number altered genes in investigated tumors. Red represents 
losses and blue represents gains. Gene list obtained from http://www.sanger.ac.uk/genetics/ 
CGP/Census/ [22]. (*) Matching left samples from these cases—MS34, MS173 and 
MS334—were not investigated, due to insufficient tumor quantity. 
 
3. Experimental Section  
3.1. Sample Acquisition, Handling and Preparation 
Fresh frozen radical prostatectomy specimens from over 1700 prostate cancer patients were 
archived between the years 1998 to 2007 in the bio-bank of the Department of Urology, University 
Hospital, Muenster, with informed consent of the patients. Prior to storage of tissue specimens, 
prostate tissue portions from the left and right apex region were embedded in ―Tissue-Tek‖ OCT 
(optimum cutting temperature) compound (Sakura Finetek, Torrance, CA, USA), briefly flash-frozen 
in liquid nitrogen and stored afterwards in 2-Methylbuthane solution at −80 ºC. Preserving these tissue 
portions from the apex region was based on evidence that tumors occur frequently in the peripheral 
zone and extend laterally into the apex region [24].  
All deposited specimens in the Department of Urology, University Hospital, Muenster, were 
accompanied with pathological reports, which contained cross-sectional views of whole prostates and 
mapped areas of adenocarcinoma (Figure 5). With the advantage of illustrative pathological reports, 
the major criterion for case selection was the presence of tumor in the apex region of the prostate, 
where the fresh frozen samples were taken. Tumor foci separated by benign tissue in the apex region 
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were necessary for selection of multifocal prostate cancer cases. Unifocal prostate cancers should 
possess a single tumor focus that extended into the apex region. Specimens obtained from the Erasmus 
Medical Center, Rotterdam, were selected based on written pathological reports, which held 
information on the anatomical location of tumor(s). From all deposited tissue specimens, 221 cases 
were selected, cut and pathologically evaluated by experienced pathologists (Elke Eltze; Mahmoud 
Abbas; Joerg Neumann; Ulf Titze and Geert J.L.H. van Leenders).  
Figure 5. Institutional routine pathology report. The documents contain cross-sectional 
views of radical prostatectomy specimens showing areas of adenocarcinoma in the prostate 
pathological mapping of (A) a multifocal prostate cancer and (B) a unifocal  
prostate cancer [24].  
  
(A) (B) 
All tissue samples and section preparations were conducted at −20 °C in a MTC bench-top cryocut 
machine (SLEE, Mainz, Germany). Tissue sections of 5 µm bordering the area of interest were cut and 
stained with hematoxylin and eosin (H&E). Stained tissue sections were afterwards reviewed by the 
pathologists. Areas of adenocarcinoma were marked on the slide(s), and unwanted tissue portions were 
macro-dissected. Repetition of the procedure was carried out until the tumor tissues reached a 
maximum achievable percentage of approximately 80%–100%.  
From the initial selection of 221 cases, prostate cancer specimens from 22 patients were afterwards 
selected based on sufficiently high tumor quantity and utilized in this study. Also included in this 
collective are additional samples obtained from a single prostate cancer patient treated at the Erasmus 
Medical Centre (EMC), Rotterdam (Table 1). Forty-one individual tumor specimens were obtained 
from these 22 patients. Twenty-eight tumor foci were obtained from 14 multifocal prostate cancers, 
and 13 tumor specimens were obtained from eight unifocal prostate cancers. Multifocal prostate 
cancers refer to patients’ specimen with two or more adenocarcinoma foci, separated by normal tissue, 
while unifocal prostate cancer consisted of a single tumor focus. In the multifocal prostate cancer 
collective, distinct tumors were obtained from the left and right part of the prostate’s apex region. With 
the unifocal prostate cancer collective, the tumor specimens were excised from the left and right side 
of the single tumor focus. Furthermore, nine non-tumor specimens were utilized in this study, which 
were comprised of eight blood samples and one histological benign tissue (Table 1).  
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From Table 1, it can be observed that investigated tumors were obtained from specimens with rather 
high tumor volume. The utilization of these cases may imply a selection bias; however, these 
specimens were necessary in order to obtain sufficient tumor percentage needed for experiments. 
Furthermore, it is important to emphasize that many multifocal tumors were not present with two 
separate foci in the apex region, i.e., more than 1,700 radical prostatectomy specimens had to be 
screened to find the relatively small number of samples that was investigated in this study. 
3.2. DNA Preparation and Quality Control 
Genomic tumor and blood cell DNA were isolated using standard protocols from the Maxwell
®
 
Promega 16 reagent kits and Maxwell
®
 Promega personal automated system (www.promega.com; 
Mannheim, Germany) [25], which ensured no cross-contamination. DNA obtained was measured for 
quality by spectrophotometric absorbance at 260 nm and 280 nm and by 1% agarose gel 
electrophoresis to assess high DNA molecularity. The microarray chips and reagents were purchased 
from Affymetrix (Santa Clara, CA, USA) and other manufacturers recommended by Affymetrix (Santa 
Clara, CA, USA). The experiments were conducted according to the Affymetrix Genome-Wide
®
 
Human SNP Array 6.0 standard protocol (Santa Clara, CA, USA).  
3.3. Genome-Wide Microarray Analysis 
Two-hundred fifty nanograms/five microliters of genomic DNA were digested with Nsp and Sty 
restriction enzymes (New England Biolabs, Herts, UK), ligated with Nsp and Sty adaptors 
(Affymetrix, Santa Clara, CA, USA) and amplified in the PCR step. PCR products of 250–1000 base 
pair (bp) fragments were purified, fragmented to lengths of 50–200 bps and labeled with biotinylated 
dideoxy ATP (Affymetrix, Santa Clara, CA, USA). These labeled probes were hybridized to the 
Affymetrix 6.0 SNP-CNV microarray chip (Santa Clara, CA, USA) at 50 °C, 60 rpm for 16 to 18 h. 
These were subsequently washed, stained and scanned with the Affymetrix Genechip
®
 Scanner 3000 
(Santa Clara, CA, USA). With the Affymetrix Genotyping Console (version 4.1.2) software [26], each 
chip experiment was quality controlled for contrast and intensity. Data produced as CEL files were 
exported for further analysis with the Partek
®
 Genomic Suite software (version 6.6) (Partek 
Incorporated, St. Louis, MO, USA) [14,27].  
3.4. Data Analysis 
Using the Partek Genomic Suite (St. Louis, MO, USA), all experimental CEL files were normalized 
against a universal reference (Hapmap 270 control samples) to analyze chromosomal regions gained 
and lost. Present on the Affymetrix microarray chip are CNV and SNP probes. For a wider and higher 
resolution of the genome, the intensity of both SNP and CNV probes were interrogated for copy 
number analysis by the genomic segmentation algorithm. The parameters for the execution of the 
genomic segmentation algorithm include: minimum genomic markers/probes of 100, p-value of  
≤0.001 and signal-to-noise ratio of 2 ± 0.3 (limits of detecting the normal range in a diploid region:  
1.7 to 2.3). The Genomic segmentation algorithm [14,28] conducts its task of copy number analysis in 
two steps: firstly, a breakpoint was established, and secondly, the aberration status of that 
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chromosomal region was ascertained. A breakpoint is recognized when a two-sided t-test statistically 
compares two neighboring regions/segments and there is a significant change in chromosomal 
abundance (p < 0.001). The aberration status of the region is thus established when a one-sided t-test 
was used to statistically compare the probe distributions mean of the chromosomal regions and the 
expected range of the normal (1.7 to 2.3). Annotations of significant regions were conducted with 
Refseq [29,30], and subsequent data handling was conducted with Microsoft
®
 Office Excel 2010 
(Microsoft Corporation, WA, USA). Hierarchical clustering was performed with the Euclidean [31] 
distance measure, which determines sample dissimilarity and average linkage. 
4. Conclusions  
Our current results show that no genetic characteristics were identified that differentiate between 
multifocal and unifocal prostate cancers. Further observations show that prostate cancer is a 
heterogeneous disease. The variations in genetic alterations observed in a single prostate draw 
attention to the multi-faceted and complex events that occur in prostate carcinogenesis. We propose 
that the problem of heterogeneity is not specific to multifocal prostate cancers, but to unifocal prostate 
cancers, as well. The genetic inconsistencies within a tumor focus and among tumor foci pose a 
challenge to comprehensive knowledge of prostate cancer biology, clinical management of prostate 
cancer and future research studies. 
Acknowledgments 
This work is funded by the European Commission FP7 Marie Curie Initial Training Network  
'PRO-NEST' (Project No. 238278). The authors wish to acknowledge Geert J.L.H. van Leenders for 
the pathological evaluation of tumor slides; Beate Pepping-Schefers, Barbara Kloke and Hilla Bürgel 
for training in fresh frozen tissue preparations; Matthias Isakiewitsch Andreas Huge and Karsten 
Heidtke for technical assistance in Partek and Affymetrix analytical tools; and Reemt Hinkelammert 
for tumor volume estimation.  
Conflict of Interest 
The authors declare no conflict of interest. 
References  
1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics.  
CA: Cancer J. Clin. 2011, 61, 69–90.  
2. Schmidt, H.; DeAngelis, G.; Eltze, E.; Gockel, I.; Semjonow, A.; Brandt, B. Asynchronous 
Growth of Prostate Cancer is Reflected by Circulating Tumor Cells Delivered from Distinct, Even 
Small Foci, Harboring Loss of Heterozygosity of the PTEN Gene. Cancer Res. 2006, 66,  
8959–8965.  
3. Arora, R.; Koch, M.O.; Eble, J.N.; Ulbright, T.M.; Li, L.; Cheng, L. Heterogeneity of Gleason 
Grade in Multifocal Adenocarcinoma of the Prostate. Cancer 2004, 100, 2362–2366.  
Int. J. Mol. Sci. 2013, 14 11828 
 
 
4. Meiers, I.; Waters, D.J.; Bostwick, D.G. Preoperative Prediction of Multifocal Prostate Cancer 
and Application of Focal Therapy: Review 2007. Urology 2007, 70, 3–8.  
5. Djavan, B.; Susani, M.; Bursa, B.; Basharkhah, A.; Simak, R.; Marberger, M. Predictability and 
Significance of Multifocal Prostate Cancer in the Radical Prostatectomy Specimen. Tech. Urol. 
1999, 5, 139–142.  
6. Andreoiu, M.; Cheng, L. Multifocal Prostate Cancer: Biologic, Prognostic, and Therapeutic 
Implications. Hum. Pathol. 2010, 41, 781–793. 
7. Ruijter, E.T.; van de Kaa, C.A.; Schalken, J.A.; Debruyne, F.M.; Ruiter, D.J. Histological Grade 
Heterogeneity in Multifocal Prostate Cancer. Biological and Clinical Implications. J. Pathol. 
1996, 180, 295–299.  
8. Eltze, E.; Schmidt, H.; Semjonow, A.; Brandt, B. Translating Genetic Pathways to Protein 
Networks for Cancer Sub-Typing. Ann. Oncol. 2008, 19, 44–47. 
9. Torring, N.; Borre, M.; Sorensen, K.D.; Andersen, C.L.; Wiuf, C.; Orntoft, T.F. Genome-Wide 
Analysis of Allelic Imbalance in Prostate Cancer using the Affymetrix 50K SNP Mapping Array. 
Br. J. Cancer 2007, 96, 499–506.  
10. Feuk, L.; Carson, A.R.; Scherer, S.W. Structural Variation in the Human Genome. Nat. Rev. 
Genet. 2006, 7, 85–97.  
11. Bettendorf, O.; Schmidt, H.; Staebler, A.; Grobholz, R.; Heinecke, A.; Boecker, W.; Hertle, L.; 
Semjonow, A. Chromosomal Imbalances, Loss of Heterozygosity, and Immunohistochemical 
Expression of TP53, RB1, and PTEN in Intraductal Cancer, Intraepithelial Neoplasia, and 
Invasive Adenocarcinoma of the Prostate. Genes Chromosomes Cancer 2008, 47, 565–572.  
12. Ribeiro, F.R.; Diep, C.B.; Jeronimo, C.; Henrique, R.; Lopes, C.; Eknaes, M.; Lingjaerde, O.C.; 
Lothe, R.A.; Teixeira, M.R. Statistical Dissection of Genetic Pathways Involved in Prostate 
Carcinogenesis. Genes Chromosomes Cancer 2006, 45, 154–163.  
13. Kallioniemi, O.P.; Visakorpi, T. Genetic Basis and Clonal Evolution of Human Prostate Cancer. 
Adv. Cancer Res. 1996, 68, 225–255.  
14. Boyd, L.K.; Mao, X.; Xue, L.; Lin, D.; Chaplin, T.; Kudahetti, S.C.; Stankiewicz, E.; Yu, Y.; 
Beltran, L.; Shaw, G.; et al. High-Resolution Genome-Wide Copy-Number Analysis Suggests a 
Monoclonal Origin of Multifocal Prostate Cancer. Genes Chromosomes Cancer 2012, 51,  
579–589.  
15. Robbins, C.M.; Tembe, W.A.; Baker, A.; Sinari, S.; Moses, T.Y.; Beckstrom-Sternberg, S.; 
Beckstrom-Sternberg, J.; Barrett, M.; Long, J.; Chinnaiyan, A.; et al. Copy Number and Targeted 
Mutational Analysis Reveals Novel Somatic Events in Metastatic Prostate Tumors. Genome Res. 
2011, 21, 47–55. 
16. Holcomb, I.N.; Grove, D.I.; Kinnunen, M.; Friedman, C.L.; Gallaher, I.S.; Morgan, T.M.;  
Sather, C.L.; Delrow, J.J.; Nelson, P.S.; Lange, P.H.; et al. Genomic Alterations Indicate Tumor 
Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients. 
Cancer Res. 2008, 68, 5599–5608.  
17. El Gammal, A.T.; Bruchmann, M.; Zustin, J.; Isbarn, H.; Hellwinkel, O.J.; Kollermann, J.;  
Sauter, G.; Simon, R.; Wilczak, W.; Schwarz, J.; et al. Chromosome 8p Deletions and 8q Gains 
are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer. Clin. Cancer Res. 
2010, 16, 56–64.  
Int. J. Mol. Sci. 2013, 14 11829 
 
 
18. Takahashi, S.; Qian, J.; Brown, J.A.; Alcaraz, A.; Bostwick, D.G.; Lieber, M.M.; Jenkins, R.B. 
Potential Markers of Prostate Cancer Aggressiveness Detected by Fluorescence in Situ 
Hybridization in Needle Biopsies. Cancer Res. 1994, 54, 3574–3579.  
19. Jenkins, R.B.; Qian, J.; Lieber, M.M.; Bostwick, D.G. Detection of c-Myc Oncogene 
Amplification and Chromosomal Anomalies in Metastatic Prostatic Carcinoma by Fluorescence 
in Situ Hybridization. Cancer Res. 1997, 57, 524–531.  
20. Ruijter, E.T.; Miller, G.J.; van de Kaa, C.A.; van Bokhoven, A.; Bussemakers, M.J.;  
Debruyne, F.M.; Ruiter, D.J.; Schalken, J.A. Molecular Analysis of Multifocal Prostate Cancer 
Lesions. J. Pathol. 1999, 188, 271–277.  
21. Rice, K.R.; Furusato, B.; Chen, Y.; McLeod, D.G.; Sesterhenn, I.A.; Brassell, 
S.A. Clinicopathological Behavior of Single Focus Prostate Adenocarcinoma. J. Urol. 2009, 182, 
2689–2694. 
22. Wellcome Trust Sanger Institute Cancer Genome Project. Cancer Gene Census. Available online: 
http://www.sanger.ac.uk/genetics/CGP/Census (accessed on 3 February 2013). 
23. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.;  
Stratton, M.R. A Census of Human Cancer Genes. Nat. Rev. Cancer 2004, 4, 177–183. 
24. Eminaga, O.; Hinkelammert, R.; Semjonow, A.; Neumann, J.; Abbas, M.; Koepke, T.;  
Bettendorf, O.; Eltze, E.; Dugas, M. Clinical Map Document Based on XML (cMDX): Document 
Architecture with Mapping Feature for Reporting and Analysing Prostate Cancer in Radical 
Prostatectomy Specimens. BMC Med. Inform. Decis. Mak. 2010, 10, 71.  
25. Maxwell Promega reagents and systems. Available online: http://www.promega.com (accessed on 
10 June 2010). 
26. Affymetrix Genotyping Console, version 4.1.2; Software for creating custom SQLite format 
annotations; Affymetrix: Santa Clara, CA, USA, 2011.  
27. Partek Genomic Suite Software, version 6.6; Software for analyzing statistics,  
Partek Inc.: St. Louis, MO, USA, 2012. 
28. Optimizing Copy Number Segmentation in Partek; Partek Inc.: St. Louis, MO, USA, 2009.  
29. Pruitt, K.D.; Tatusova, T.; Maglott, D.R. NCBI Reference Sequences (RefSeq): A Curated  
Non-Redundant Sequence Database of Genomes, Transcripts and Proteins. Nucleic Acids Res. 
2007, 35, 61–65. 
30. User Guide: Associating a Spreadsheet with an Annotation File in Partek Genomics Suite; Partek 
Inc.: St. Louis, MO, USA, 2010. 
31. User Guide: Hierarchical Clustering Analysis of Microarray Data; Partek Inc.: St. Louis,  
MO, USA, 2009. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
